PPAR-γ mitigates NAFLD progression, by regulating adipocytokine expression, preventing insulin resistance [47], and stimulating CPT-1β activity, to promote fatty-acid oxidation [48]. Here, CPT1B is linked to metabolic dysfunction-associated steatotic liver disease.